Ju, C;
Lau, WCY;
Hayes, JF;
Osborn, D;
Man, KKC;
Chan, EW;
Wong, ICK;
(2021)
Impact of the COVID-19 pandemic on use of anti-dementia medications in 34 European and North American countries.
Alzheimer’s & Dementia: Translational Research & Clinical Intervention
, 7
(1)
, Article e12206.
Preview |
Text
Wei_A D Transl Res Clin Interv - 2021 - Ju - Impact of the COVID‐19 pandemic on use of anti‐dementia medications in 34.pdf Download (549kB) | Preview |
Abstract
INTRODUCTION: The impact of the COVID-19 pandemic on the global use of anti-dementia medication is unknown. We aimed to determine the changes of anti-dementia medication use in Europe (EU) and North America (NA) during the pandemic. METHODS: This is a cross-sectional study using sales data of anti-dementia medications in 2019 and 2020 from 34 EU and NA countries. The monthly uses of anti-dementia medications from January through June in 2020 were compared to the corresponding months in 2019 for each country. RESULTS: In the pre-pandemic period of January to March 2020, 70 out of 102 (3 months x 34 countries) measurements (68.6%) of monthly sales volume showed an increase. In contrast, 76.5% and 85.3% countries showed reduced sales in April and May 2020, respectively. DISCUSSION: These findings indicate changes in use of anti-dementia medications during the pandemic. The delivery of pharmaceutical care for dementia patients may be heavily disrupted in certain countries.
| Type: | Article |
|---|---|
| Title: | Impact of the COVID-19 pandemic on use of anti-dementia medications in 34 European and North American countries |
| Open access status: | An open access version is available from UCL Discovery |
| Publisher version: | https://doi.org/10.1002/trc2.12206 |
| Language: | English |
| Additional information: | © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Anti-dementiamedications,COVID-19,dementia,globalhealth |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10132214 |
Archive Staff Only
 |
View Item |
